Augmenting engineered T-cell strategies in solid cancers through epigenetic priming

Area of Science:

• Immunotherapy
• Cancer Biology
• Epigenetics

Background:

• T-cell receptor (TCR) and chimeric antigen receptor (CAR)-based adoptive cell transfer (ACT) therapies have shown success in hematological malignancies.
• However, ACT efficacy in solid tumors is limited by challenges including target identification, antigen heterogeneity, T-cell trafficking, and the tumor microenvironment (TME).

Purpose of the Study:

• To review the current literature on ACT for solid tumors.
• To explore the potential of combining epigenetic modulators with ACT strategies to overcome current limitations.

Main Methods:

• Literature review of existing studies on ACT in solid tumors.
• Analysis of challenges hindering ACT efficacy in solid tumors.
• Exploration of epigenetic priming as a strategy to enhance T-cell function.

Main Results:

• Solid tumors present unique hurdles for ACT compared to hematological cancers.
• Epigenetic modifications of tumor cells and the TME are potential strategies to improve ACT outcomes.
• Combining epigenetic modulators with ACT may augment the efficacy of TCR- and CAR-engineered T cells.

Conclusions:

• ACT for solid tumors requires innovative approaches to overcome inherent biological barriers.
• Epigenetic modulation presents a promising avenue for enhancing the effectiveness of engineered T-cell therapies.
• Future research should focus on integrating epigenetic therapies with ACT to improve clinical outcomes in solid cancer treatment.